Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

The coffee advice given to atrial fibrillation patients may deserve a rethink

12

Aug 2026

The coffee advice given to atrial fibrillation patients may deserve a rethink

The DECAF randomized trial found that adults with persistent atrial fibrillation or atrial flutter assigned to drink at least one cup of caffeinated coffee daily had a 39% lower hazard of recurrent clinically detected AF or flutter than those assigned to avoid coffee and caffeine. The findings challenge longstanding advice to routinely restrict caffeinated coffee in people with AF, while further research is needed to determine whether coffee itself provides a protective effect.

Cannabis compounds may weaken glioblastoma response to chemotherapy and radiation

12

Aug 2026

Cannabis compounds may weaken glioblastoma response to chemotherapy and radiation

Several cannabinoids reduced chemotherapy- and radiation-induced apoptosis in glioblastoma cell models, with effects linked to reduced apoptotic priming, increased pro-survival signaling, and G1 cell-cycle arrest. The findings raise concern that cannabinoid exposure could interfere with some cancer treatments, although the results are limited to laboratory models and require in vivo and clinical validation.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.